Interleukin-6 dan High-Sensitivity C-Reactive Protein sebagai Biomarker Komplikasi Diabetes Mellitus Tipe 2

Desi Oktariana; Farah Yumna  Putri

doi:10.31539/ehydzc64

Authors

Desi Oktariana Universitas Sriwijaya
Farah Yumna Putri Universitas Sriwijaya

DOI:

https://doi.org/10.31539/ehydzc64

Abstract

This review aimed to assess the consistency of the associations between IL-6 and hs-CRP and T2DM complications, as well as the readiness of the evidence for risk stratification. The systematic review followed PRISMA 2020 guidelines. PubMed, ScienceDirect, and SpringerLink were searched for observational studies published between 2021 and 2026. Risk of bias was assessed using JBI instruments, and results were synthesized narratively according to SWiM guidelines. Eleven studies met the inclusion criteria. IL-6 showed associations with heart failure, retinopathy and macular edema, cardiovascular autonomic neuropathy, peripheral artery disease, and diabetic foot. hs-CRP was linked to mortality, diabetic kidney disease, and retinopathy, though independent associations were inconsistent regarding cardiovascular events and non-proliferative diabetic retinopathy (NPDR). Heterogeneity in study design, assays, matrices, and the control of confounders precluded meta-analysis. In conclusion, IL-6 and hs-CRP capture distinct inflammatory dimensions and potentially complement conventional risk assessment, yet they are not sufficiently validated for use as standalone tests.

Keywords: Diabetic Complications, High-Sensitivity C-Reactive Protein, Inflammatory Biomarkers, Interleukin-6, Type 2 Diabetes Mellitus.

References

Barker, T. H., Hasanoff, S., Aromataris, E., Stone, J. C., Leonardi-Bee, J., Sears, K., et al. (2025). The revised JBI critical appraisal tool for the assessment of risk of bias for cohort studies. JBI Evidence Synthesis, 23(3), 441-453. https://doi.org/10.11124/JBIES-24-00103

Bhutia, C. U., Kaur, P., Singh, K., & Kaur, S. (2023). Evaluating peripheral blood inflammatory and metabolic biomarkers as predictors in diabetic retinopathy and diabetic macular edema. Indian Journal of Ophthalmology, 71(6), 2521–2525. https://doi.org/10.4103/IJO.IJO_345_23

Damgaard, M., Kokla, M., Gerwig, R. H., et al. (2026). Severity of cardiovascular autonomic neuropathy is linked to increasing levels of circulating proinflammatory cytokines. Diabetes, Obesity and Metabolism, 28(10), 9356–9366. https://doi.org/10.1111/dom.71066

Fang, Y., Wang, B., Pang, B., et al. (2024). Exploring the relations of NLR, hsCRP and MCP-1 with type 2 diabetic kidney disease: A cross-sectional study. Scientific Reports, 14(1), 3211. https://doi.org/10.1038/s41598-024-53567-2

Forbes, J. M., & Cooper, M. E. (2013). Mechanisms of diabetic complications. Physiological Reviews, 93(1), 137–188. https://doi.org/10.1152/physrev.00045.2011

Gameil, M. A., Abdelhay, H., Ibrahim, Y., & Hakim, A. (2023). Potential impact of epicardial fat thickness, pentraxin-3, and high-sensitive C-reactive protein on the risk of non-proliferative diabetic retinopathy. Journal of Diabetes & Metabolic Disorders, 22(1), 735–742. https://doi.org/10.1007/s40200-023-01195-4

Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (Eds.). (2024). Cochrane handbook for systematic reviews of interventions (Version 6.5). Cochrane. https://training.cochrane.org/handbook/current

Hoes, L. L. F., Riksen, N. P., Geleijnse, J. M., et al. (2024). Relationship of neutrophil-to-lymphocyte ratio, in addition to C-reactive protein, with cardiovascular events in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 213, 111727. https://doi.org/10.1016/j.diabres.2024.111727

Hunter, C. A., & Jones, S. A. (2015). IL-6 as a keystone cytokine in health and disease. Nature Immunology, 16(5), 448–457. https://doi.org/10.1038/ni.3153

International Diabetes Federation. (2025). IDF diabetes atlas (11th ed.). https://diabetesatlas.org/

Ioannidis, J. P. A., & Bossuyt, P. M. M. (2017). Waste, leaks, and failures in the biomarker pipeline. Clinical Chemistry, 63(5), 963–972. https://doi.org/10.1373/clinchem.2016.254649

JBI. (2024). JBI manual for evidence synthesis. JBI. https://jbi-global-wiki.refined.site/space/MANUAL

Jin, Z., Zhang, Q., Liu, K., et al. (2024). The association between interleukin family and diabetes mellitus and its complications: An overview of systematic reviews and meta-analyses. Diabetes Research and Clinical Practice, 210, 111615. https://doi.org/10.1016/j.diabres.2024.111615

Li, Y., Liu, Y., Liu, S., et al. (2023). Diabetic vascular diseases: Molecular mechanisms and therapeutic strategies. Signal Transduction and Targeted Therapy, 8, 152. https://doi.org/10.1038/s41392-023-01400-z

Manda, A. R., Lee, L. H., Steinkerchner, M. S., et al. (2026). Analysis of aqueous interleukin-6 in diabetic retinopathy: A prospective, controlled trial of 328 eyes. Ophthalmology Retina, 10(1), 81–87. https://doi.org/10.1016/j.oret.2025.06.014

Mohamed, A. A., Hussein, M. A. E., Hanna, I. N., et al. (2024). The potential impact and diagnostic value of inflammatory markers on diabetic foot progression in type II diabetes mellitus: A case-control study. Medicina Clínica, 162(9), e33–e39. https://doi.org/10.1016/j.medcli.2024.01.009

Okdahl, T., Wegeberg, A. M., Pociot, F., Brock, B., Størling, J., & Brock, C. (2022). Low-grade inflammation in type 2 diabetes: A cross-sectional study from a Danish diabetes outpatient clinic. BMJ Open, 12(12), e062188. https://doi.org/10.1136/bmjopen-2022-062188

Page, M. J., McKenzie, J. E., Bossuyt, P. M., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71

Pellegrini, V., La Grotta, R., Carreras, F., et al. (2024). Inflammatory trajectory of type 2 diabetes: Novel opportunities for early and late treatment. Cells, 13(19), 1662. https://doi.org/10.3390/cells13191662

Pencina, M. J., D’Agostino, R. B., Sr., D’Agostino, R. B., Jr., & Vasan, R. S. (2008). Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Statistics in Medicine, 27(2), 157–172. https://doi.org/10.1002/sim.2929

Remmelzwaal, S., Yeung, S. M. H., Blom, M. T., et al. (2024). Increased interleukin-6 is associated with higher risk of heart failure in people with type 2 diabetes. ESC Heart Failure, 11(4), 2442–2446. https://doi.org/10.1002/ehf2.14743

Ridker, P. M. (2016). From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circulation Research, 118(1), 145–156. https://doi.org/10.1161/CIRCRESAHA.115.306656

Riley, R. D., Debray, T. P. A., Collins, G. S., et al. (2021). Minimum sample size for external validation of a clinical prediction model with a binary outcome. Statistics in Medicine, 40(19), 4230–4251. https://doi.org/10.1002/sim.9025

Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022). Inflammation in obesity, diabetes, and related disorders. Immunity, 55(1), 31-55. https://doi.org/10.1016/j.immuni.2021.12.013

Sharif, S., van der Graaf, Y., Cramer, M. J., et al. (2021). Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. Cardiovascular Diabetology, 20, 220. https://doi.org/10.1186/s12933-021-01409-0

Sproston, N. R., & Ashworth, J. J. (2018). Role of C-reactive protein at sites of inflammation and infection. Frontiers in Immunology, 9, 754. https://doi.org/10.3389/fimmu.2018.00754

Stanimirovic, J., Radovanovic, J., Banjac, K., et al. (2022). Role of C-reactive protein in diabetic inflammation. Mediators of Inflammation, 2022, 3706500. https://doi.org/10.1155/2022/3706500

Tanaka, T., Narazaki, M., & Kishimoto, T. (2014). IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspectives in Biology, 6(10), a016295. https://doi.org/10.1101/cshperspect.a016295

Tang, M., Cao, H., Wei, X. H., et al. (2022). Association between high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes mellitus. Frontiers in Endocrinology, 13, 885516. https://doi.org/10.3389/fendo.2022.885516

Vickers, A. J., & Elkin, E. B. (2006). Decision curve analysis: A novel method for evaluating prediction models. Medical Decision Making, 26(6), 565–574. https://doi.org/10.1177/0272989X06295361

Wang, X., Bao, W., Liu, J., et al. (2013). Inflammatory markers and risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Care, 36(1), 166–175. https://doi.org/10.2337/dc12-0702

Yang, D. R., Wang, M. Y., Zhang, C. L., & Wang, Y. (2024). Endothelial dysfunction in vascular complications of diabetes: A comprehensive review of mechanisms and implications. Frontiers in Endocrinology, 15, 1359255. https://doi.org/10.3389/fendo.2024.1359255

Zaib, S., Ahmad, S., Khan, I., Bin Jardan, Y. A., & Wondmie, G. F. (2024). An evaluation of inflammatory and endothelial dysfunction markers as determinants of peripheral arterial disease in those with diabetes mellitus. Scientific Reports, 14, 15348. https://doi.org/10.1038/s41598-024-65188-w